Open an Ambulatory Infusion Center (AIC)

1. 1

   Pick the disease and drug mix, and secure referrals

   Infusion demand comes from chronic conditions in rheumatology, gastroenterology, neurology, immunology, and oncology-adjacent care. The center's economics depend on which drugs you administer and which physicians refer patients. Line up referral relationships (or your own physician group's patients) and confirm the target drugs are reimbursed adequately in your market before you commit. Referral flow is the revenue engine.

2. 2

   Solve the buy-and-bill working-capital gap first

   Under buy-and-bill, you purchase the drug, administer it, then bill the payer, and reimbursement lags 30 to 60 days while drugs cost 32,000 to 136,000 dollars per patient per year. A growing center can exhaust its cash buying inventory faster than reimbursements arrive. Solve this before opening: a working-capital line, a specialty-distributor credit arrangement, or a buy-and-bill bridge-lending product (a separate card in this file). Do not open without a financing answer to this gap.

3. 3

   Set up drug distribution and the revenue cycle

   You need accounts with specialty drug distributors, the right handling and cold-chain storage, and a revenue cycle that handles buy-and-bill billing, prior authorization, and the white-bagging or brown-bagging requirements some payers and PBMs impose. Prior-authorization and eligibility software (a separate card) reduces the denials and cancellations that otherwise crush margin. Billing errors on a 100,000-dollar drug are expensive mistakes.

4. 4

   Get licensed and payer-contracted

   The center needs state licensing appropriate to an infusion facility, pharmacy or drug-handling compliance as your state requires, and in-network contracts with the commercial payers and Medicare that cover your patients' drugs. Credentialing lags months, so start during build-out. Confirm each payer's site-of-care and white-bagging policy, because it directly changes whether you buy the drug or the pharmacy supplies it.

5. 5

   Build a chair-utilization operation

   The physical constraint is infusion chairs and nursing hours; the profit lever is chair utilization, scheduled tightly so chairs and nurses are not idle. Infusion visits can run hours, so scheduling optimization (a separate AI card in this file covers OR and infusion-chair scheduling) meaningfully raises revenue per chair. Staff with infusion-trained nurses and a pharmacist relationship sized to volume.

6. 6

   Plan for biosimilar and white-bagging pressure

   Two structural risks compress margin over time: biosimilars lower the price (and the buy-and-bill margin) of reference biologics, and payer white-bagging (requiring the drug come from their specialty pharmacy) can take the drug margin away entirely. Diversify the drug mix, and consider an in-house specialty pharmacy layer (a separate card) to protect referral conversion and reduce PBM white-bagging dependence. Build the business to survive drug-margin erosion, not to depend on it.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Operators or physician groups (rheumatology, GI, neurology, oncology-adjacent) who can finance the drug working-capital gap

Not for: Not for an operator who cannot or will not finance the buy-and-bill working-capital gap; that gap is the whole game and it sinks the undercapitalized. Not for someone who wants to deliver infusions in patients' homes rather than at a center; that is the home infusion services provider, a separate card. And not for anyone expecting the current drug margin to last forever, because biosimilars and white-bagging are structurally compressing it.